FLT3 and acute myeloid leukemia: A number of studies have attempted to improve outcomes for relapsed FLT3 mutated AML by combining FLT3i with other targeted therapies [9, 10], however no comparative studies have yet been performed and results from early combination studies have shown only modest improvements in response at the cost of substantial toxicity.